Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Show all 37 references

Sorted by citations

Items 901–1,000 of 1,000

Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI–resistant lung cancer
Kakuto, S., Uchibori, K., Yamamoto, Y., Miyauchi, E., Nishio, M., Sugiura, H., & Katayama, R. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108833 · Cited by 1
ASIC3–PLCG1 axis–driven macropinocytosis promotes osimertinib drug-tolerant persistence in malignant pleural effusion–associated NSCLC
Huang, W., Wang, C.-Y., Chen, Y., Lin, Y., Changchien, C., Chian, C., & Tsai, C. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107417 · Cited by 1
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge
Bassil, C. F., Dillon, K. A., Anderson, G. R., Mayro, B., Askin, K. N., Winter, P. S., Harry, S. A., Gruber, S., Hall, T. M., Hoj, J. P., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68424-1 · Cited by 2
Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115840 · Cited by 2
A network-based deep learning model integrating subclonal architecture for therapy response prediction in cancer
Kim, S., Ha, D., Nam, A.-R., Cheong, S., Lee, J., Kim, S., & Park, S. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101411 · Cited by 1
Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer
Zhu, H., Wang, Y., Wu, Y., Li, R. Q., & Zhou, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864068 · Cited by 1
Self-citation
Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies
Guo, J., Wen, Q., & Fan, S. (2026) · MedComm · doi:10.1002/mco2.70823 · Cited by 2
Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer
Saporita, I., Farinea, G., Lombardi, E., Bironzo, P., Novello, S., & Passiglia, F. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2706458 · Cited by 1
Oncolytic Viruses and the Eradication of Drug-Resistant Tumor Cells
Komarova, N. L., & Wodarz, D. (2013) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-1-4614-8301-4_15 · Cited by 1
Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms
Köhler, J., & Schüler, M. (2011) · Der Onkologe · doi:10.1007/s00761-011-2036-6 · Cited by 1
From Single-Gene to Multiplex Analysis in Lung Cancer, Challenges and Accomplishments: A Review of a Single Institution’s Experience
Zhao, W., Damodaran, S., & Villalona-Calero, M. A. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.23 · Cited by 1
Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer
Montagut, C. O., & Albanell, J. (2012) · Colorectal Cancer · doi:10.2217/crc.12.62 · Cited by 1
Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC
Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1
Drifting EGFR mutation.
Noro, R., & Yamada, T. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.08 · Cited by 1
Principles of Chemotherapy
Izar, B., Ryan, D. P., & Chabner, B. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00009-5 · Cited by 1
Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck
Schmitz, S., & Machiels, J. (2017) · Springer eBooks · doi:10.1007/978-94-024-1084-6_6 · Cited by 1
EGFR Resistance
Bourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
Hamdi, A. I. F., How, S. H., Islam, M. K., Lim, J. C. W., & Stanslas, J. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2147671 · Cited by 1
Molecular Pathology of Lung Tumors
Lo, Y., & Lindeman, N. I. (2023) · Springer eBooks · doi:10.1007/978-3-031-35118-1_9 · Cited by 1
Self-citation
Latest progress in tyrosine kinase inhibitors
Pospelova, T. V., & Pospelov, V. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1836 · Cited by 1
Therapeutic potential of c-MET inhibitors: background and clinical data
Organ, S. L., Sierra, J. R., & Tsao, M. (2012) · Clinical Investigation · doi:10.4155/cli.12.11 · Cited by 1
Evolving Treatment Paradigms in Non-Small Cell Lung Cancer
Mileham, K. F., Brooks, H. D., & Kim, E. S. (2012) · Cited by 1
Egfr Ca Repeat Polymorphism Predict Clinical Outcome in Egfr Mutation Positive Nsclc Patients Treated with Erlotinib
Larsen, A. W., Nissen, P. H., Meldgaard, P., & Sørensen, B. S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.98 · Cited by 1
Mechanisms and Overcome of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Soh, J., Toyooka, S., Ueno, T., & Miyoshi, S. (2012) · Haigan · doi:10.2482/haigan.52.131 · Cited by 1
The Response of Cancer Cell Populations to Therapies
Lindsay, D., Garvey, C. M., Mumenthaler, S. M., & Foo, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804310-3.00010-7 · Cited by 1
[Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy in Advanced NSCLC Patients with EGFR Mutations].
Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.02.04 · Cited by 1
Indirect Analysis of First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Mutations in a Japanese Population
Nakagawa, K., Matsumura, K., Scory, T. D., Farris, M. S., Larkin-Kaiser, K. A., Kikkawa, H., Ivanova, J. I., & Wilner, K. D. (2020) · Future Oncology · doi:10.2217/fon-2020-0651 · Cited by 1
Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma
Yılmaz, Y., Batur, T., Korhan, P., Öztürk, M., & Atabey, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-78737-0_21 · Cited by 1
Signaling pathways in CRC
Santos, V. S., Lago, N. M., García, C. P., García, A. P., & Aparicio, L. M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00043-0 · Cited by 1
Targeting the c‐Met Kinase
Tang, C. Z., Cortez, M. A., Hong, D. S., & Welsh, J. W. (2015) · doi:10.1002/9781118468678.ch34 · Cited by 1
EGFR inhibitors in cancer treatment
Ciardiello, F. (2012) · doi:10.2217/ebo.11.398 · Cited by 1
Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic targetPreprint
Peacock, J. D., Pridgeon, M. G., Tovar, E. A., Essenburg, C. J., Bowman, M. J., Madaj, Z., Koeman, J. M., Grit, J. L., Dodd, R. D., Cardona, D. M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/199000 · Cited by 1
A combinatorial extracellular code tunes the intracellular signaling network activity to distinct cellular responsesPreprint
Kuchenov, D., Ziebell, F., Salopiata, F., Citir, M., Klingmüller, U., Huber, W. K., & Schultz, C. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/346957 · Cited by 1
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressuresPreprint
Velde, R. V., Yoon, N., Marusyk, V., Durmaz, A., Dhawan, A., Myroshnychenko, D., Lozano-Peral, D., Desai, B., Balynska, O., Poleszhuk, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/504837 · Cited by 1
Signal Transduction in Disease
Ganey, P. E., & Misek, S. A. (2019) · Wiley eBooks · doi:10.1002/9781119060208.ch4 · Cited by 1
Systematic analysis of network-driven adaptive resistance to CDK4/6 and oestrogen receptor inhibition using meta-dynamic network modellingPreprint
Hart, A., Shin, S., & Nguyen, L. K. (2023) · eLife · doi:10.7554/elife.87710 · Cited by 1
Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsPreprint
Creixell, M., Taylor, S. D., Gerritsen, J. S., Bae, S. Y., Jiang, M., Augustin, T., Loui, M., Boixo, C., Creixell, P., White, F. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563266 · Cited by 1
Identifiying oncogenic drivers in NSCLC cells harboring EGFR kinase domain mutation with resistance to EGFR TKI and mesenchymal phenotype
Gao, Y. (2014)
A systems approach to uncovering the adaptive response of cancer to targeted therapies
Randall, A. (2012) · DSpace@MIT (Massachusetts Institute of Technology)
Mean-field dynamics of tumor growth and control using low-impact chemopreventionPreprint
Akhmetzhanov, A. R., & Hochberg, M. (2014) · arXiv (Cornell University) · doi:10.48550/arxiv.1408.6052
Signaling and Feedback Networks Underlying Senstivity and Resistance to Kinase Inhibitors in Oncogene Addicted Cancers
Schrock, A. B. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
THE MET RECEPTOR TYROSINE KINASE IS A POTENTIAL THERAPEUTIC TARGET IN COMBINATION WITH RADIATION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
Wu, R. (2012) · TSpace (University of Toronto)
Significance, Mechanisms, and Progress of Anticancer Drugs Targeting HGF-Met
Sakai, K., Nakamura, T., Suzuki, Y., & Matsumoto, K. (2011) · InTech eBooks · doi:10.5772/22241
Resistance to Tyrosine Kinase Inhibitors in EGFR-mutant of Non-Small Cell Lung Cancer
Murakami, A., Takahashi, F., Yunus, F., & Takahashi, K. (2012) · Journal Of The Indonesian Medical Association
Mechanisms of resistance to EGFR inhibitors in colorectal cancers
Dhillon, T. (2014) · Colorectal Cancer · doi:10.2217/crc.14.37
Searching a multicellular model to tame tumor-induced angiogenesis
Podgorski, G. J., & Flann, N. S. (2012) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb.2012.6217251
JSM Clinical Oncology and Research
(2024) · JSM Clinical Oncology and Research · doi:10.47739/2373938x/oncology
Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine
Ozenne, P. (2011)
CSIG-07EGFRvIII MEDIATED TRANSACTIVATION OF RECEPTOR TYROSINE KINASES IN GLIOMA: MECHANISM AND THERAPEUTIC IMPLICATIONS
Johns, T. G., Greenall, S., Donoghue, J. F., & Adams, T. E. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov210.07
Reviewmechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010)
Molecular Biology of Lung Cancer
Toyooka, S., Mitsudomi, T., Soh, J., Yamamoto, H., & Miyoshi, S. (2010) · Haigan · doi:10.2482/haigan.50.329
Study of Molecular Mechanisms of Sensitivity and Resistance to EGFR-Targeted Therapy in Lung Cancer
Zhang, Z. (2010) · OhioLink ETD Center (Ohio Library and Information Network)
154P: Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
Gao, H., Wu, Y.-L. L. C., Yang, J., & Zhang, X.-C. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30264-7
Self-citation
Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
Ghosh, P., Qiu, Y., Wang, L., & Kung, H. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.009
The Evolutionary Foundations of Cancer Research
Maley, C. C. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6460-4_1
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
Mirone, G., Perna, S., & Marfè, G. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_2
Tumor Genomic Profiling Reports from Different Vendors: A Comparison with Respect to Clinical Action Ability of the Provided Data
Mori, Y. (2016) · Advances in Molecular Diagnostics · doi:10.4172/2572-5645.1000110
The receptor tyrosine kinase Met and the protein tyrosine phosphatase PTPN2 in breast cancer
Veenstra, C. (2017) · Linköping University medical dissertations · doi:10.3384/diss.diva-135047
Mechanisms of IKBKE Activation in Cancer
Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)
Cancer Mutant Lung EGFR HGF-Mediated Resistance to EGFR-TKIs in Transient PI3K Inhibition Induces Apoptosis and Overcomes
Donev, I. S., Wang, W., & Yamada, T. (2011)
Breast Cancer Genomics
Scaltriti, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_15
Distilling Data Into Action: Recent Advances in the Management of Advanced Non–Small Cell Lung Cancer
Attarian, S., Goradia, N., Levy, B. P., & Halmos, A. B. (2017) · American Journal of Hematology / Oncology®
MET and RON Receptor Tyrosine Kinases as Therapeutic Antibody Targets for Cancer
Wortinger, M. A., Tetreault, J. W., Loizos, N., & Liu, L. (2018) · doi:10.1002/9781119300229.ch7
Targeting HGF with Antibodies as an Anti‐Cancer Therapeutic Strategy
Silva, D. D., Roy, A., & Bottaro, D. (2018) · doi:10.1002/9781119300229.ch6
The Role of HGF / MET and MSP / RON Signaling in Tumor Progression and Resistance to Anticancer Therapy
Klampfer, L., & Owusu, B. Y. (2018) · doi:10.1002/9781119300229.ch2
HGFR/MET and ALK inhibitors
Kwak, E. L. (2012) · doi:10.2217/ebo.12.67
MATHEMATICAL MODELING AND OPTIMIZATION OF TARGETED TUMOR THERAPY
Bogdanov, A. (2018) · Practical oncology · doi:10.31917/1902117
Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies
Bhaskar, L. V., & Saikrishna, L. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_14
The role of POPX2 in the regulation of hippo pathway
Muhammad, B. R. (2018) · doi:10.32657/10220/46579
Functions of nuclear receptors in cancer metabolism
와이라구, 페. (2014) · YUHSpace (Yonsei University Medical Library)
Targeting the Triple-Negative Breast Cancer Kinome with Chemical Proteomics
Whittle, M. C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/p21s-v784
In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectabilityPreprint
Müller, N., Brägelmann, J., Lorenz, C., Michel, U. P., Plenker, D., Ortiz‐Cuaran, S., Weiss, J. M., Büttner, R., Peifer, M., Thomas, R. K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/756593
Cancer of the Esophagus
Blackstock, A. W., & Russo, S. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00045-9
Principles of Chemotherapy
Baszkowsky, L. S., Supko, J. G., & Chabner, B. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00008-0
Liquid Biopsy: A New Diagnostic Strategy and Not Only for Lung Cancer?
Scarpino, S., & Malapelle, U. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94838
MiR-154-5p Inhibits Prostate Cancer Bone Metastasis by Inactivating PI3K/AKT SignalingPreprint
Ren, D., Yuan, X., Cao, J., Wang, B., Li, R., Zhang, R., Liu, B., Wu, M., Ren, L., Meng, Z., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-840996/v1
Faculty Opinions recommendation of Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Cook, S. J. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717950610.793463804
Lung Carcinoma
Arcila, M. E., Chang, J. C., & Tafe, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_6
Molecular Targeted Therapies in Head and Neck Cancer
Morris, Z. S., Traynor, A. M., & Harari, P. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27601-4_20
Lung Cancer
Aisner, D. L., Doebele, R. C., Varella‐Garcia, M., & Franklin, W. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_32
Met inhibitors in the treatment of lung cancer: the evidence to date
Hamilton, G., & Rath, B. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2062227
MET
Asmar, R., & Halmos, B. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_87-1
Gab1
Vaillancourt, R., Spilker, A. C., & Park, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_340
Investigating post-translational modifications of c-Met in cancer
Wagner, H. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.203995
Gab1
Vaillancourt, R., Spilker, A. C., & Park, M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0461-4_340
MET
Asmar, R., & Halmos, B. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_87
Crizotinib
Cui, J., Kania, R. S., & Edwards, M. P. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch03
Thérapies ciblées et carcinomes non à petites cellules : nouveautés
Stauber, R., Louis Gro, S., Nguyen‐Ngoc, T., Mederos, N., Bouchaab, H., Peters, S., & Abdelhamid, K. (2022) · JMIG · doi:10.53738/revmed.2022.18.782.970
Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGSPreprint
Xu, Z., Li, Y., Wang, L., Hao, X., Ying, J., Li, J., & Xing, P. (2023) · Research Square · doi:10.21203/rs.3.rs-2486337/v1
A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors
Li, T., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00005-5
MCB-613 exploits a collateral sensitivity in drug resistant EGFR -mutant non-small cell lung cancer through covalent inhibition of KEAP1Preprint
Bassil, C. F., Anderson, G. R., Mayro, B., Askin, K. N., Winter, P. S., Gruber, S., Hall, T. M., Hoj, J. P., Cerda-Smith, C. G., Hutchinson, H. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.17.524094
Targeted Therapies: A Molecular Overview
Özveren, B., & Narter, F. (2023) · Bulletin of Urooncology · doi:10.4274/uob.galenos.2022.2022.4.1
HGF-mediated c-met signaling in human corneal epithelial cells.
Tarvestad-Laise, K. E. (2022) · doi:10.18297/etd/4019
Data from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
Rottenberg, S., Vollebergh, M. A., de Hoon, B., de Ronde, J., Schouten, P. C., Kersbergen, A. J., Zander, S. A. L., Pajic, M., Jaspers, J. E., Jonkers, M., et al. (2023) · doi:10.1158/0008-5472.c.6503906.v1
Data from Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Donev, I. S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., & Yano, S. (2023) · doi:10.1158/1078-0432.c.6519006.v1
Supplementary Materials and Methods from MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2023) · doi:10.1158/0008-5472.22392192.v1
Self-citation
Data from Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2023) · doi:10.1158/1078-0432.c.6519117
Data from Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wang, W., Li, Q., Takeuchi, S., Yamada, T., Koizumi, H., Nakamura, T., Matsumoto, K., Mukaida, N., Nishioka, Y., Sone, S., et al. (2023) · doi:10.1158/1078-0432.c.6521184
Data from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2023) · doi:10.1158/1078-0432.c.6519908.v1
Data from InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2023) · doi:10.1158/1078-0432.c.6524027.v1

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks